---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000770"
form_type: "8-K/A"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:08:23.015143+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aclaris discloses interim CEO Neal Walker's compensation: $500k salary, equity awards

## Summary
- Douglas Manion stepped down as CEO/President effective Jan 16, 2024; no disagreement.
- Neal Walker appointed Interim CEO; receives $500,000 base salary, bonus eligible at 60% of base.
- Granted stock option for 497,000 shares at $1.20 per share, vesting monthly over 15 months.
- Also granted RSU for 142,000 shares with same 15-month monthly vesting and change-in-control acceleration.

## SEC filing metadata
- accession: 0001558370-24-000770
- form_type: 8-K/A
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024000770/0001558370-24-000770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024000770/acrs-20240115x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000770
- JSON: https://secwatch.observer/filing/0001558370-24-000770.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000770.txt

## Key facts
- Executive change
  Neal Walker was appointed as Interim Chief Executive Officer and President at Aclaris Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer and President
  source text: in connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024000770/0001558370-24-000770-index.htm
- Executive change
  Douglas Manion resigned as Chief Executive Officer and President at Aclaris Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer and President
  source text: On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “ Board ”), effective January 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024000770/0001558370-24-000770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.